呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者

2022-02-01 Allan MedSci原创

哮喘DupixentIL-4/IL-13单抗Dupixent
关注

Dupilumab是一种人IgG4抗体，能够抗IL-4受体 (IL-4R) α亚基，可阻断由IL-4和IL-13诱导的IL-4R信号传导，下调驱动2型炎症性疾病的分子途径。

哮喘是儿童最常见的慢性疾病之一，全球11.6%的6至7岁儿童受到影响。儿童哮喘发病率高于成人，英国约有100万儿童正在接受治疗。高达85%的哮喘儿童患有2型炎症，并且更有可能承受更高的疾病负担。严重的哮喘会影响儿童正在发育的气道，还会导致危及生命的恶化，而不受控制的哮喘会干扰儿童的日常活动，例如睡眠、上学和运动。

近日，欧盟人用药品委员会 (CHMP) 建议批准 Dupixent (dupilumab) 用于治疗6至11岁患有严重哮喘和2型炎症的儿童。预计欧盟委员会 (EC) 将在未来几个月内宣布有关Dupixent申请的最终决定。

该建议基于关键的III期试验，该试验显示，在6至11岁儿童中，添加到标准护理治疗中的Dupixent在两周内显著减少了严重哮喘的发作并改善了肺功能。

Dupilumab是一种人IgG4，能够抗IL-4受体 (IL-4R) α亚基，可阻断由IL-4和IL-13诱导的IL-4R信号传导，下调驱动2型炎症性疾病的分子途径。Dupixent已被推荐用于治疗该年龄段患有2型炎症的儿童，其特征是血液嗜酸性粒细胞升高或呼出气一氧化氮 (FeNO) 升高。嗜酸性粒细胞是免疫系统中的白细胞和主要效应细胞。然而，作为过敏性疾病炎症过程的一部分，它们可能具有破坏性——嗜酸性粒细胞积聚会导致过敏性哮喘症状。

尽管可以使用当前标准的吸入性皮质类固醇和支气管扩张剂进行治疗，但患有2型炎症的儿童可能会继续出现严重的症状，例如咳嗽、喘息和呼吸困难。

 

原始出处：

https://www.pharmatimes.com/news/chmp_approves_dupixent_for_young_children_with_asthma_1387002

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784849, encodeId=70a51e8484943, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Dec 22 05:50:27 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302708, encodeId=7cc91302e08fa, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372752, encodeId=d1fb13e275295, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189586, encodeId=67e8118958642, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbeb6410632, createdName=ms3000002047025461, createdTime=Tue Feb 01 20:36:30 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-12-22 yanjie6253_56072842

    #Dupixen#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1784849, encodeId=70a51e8484943, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Dec 22 05:50:27 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302708, encodeId=7cc91302e08fa, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372752, encodeId=d1fb13e275295, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189586, encodeId=67e8118958642, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbeb6410632, createdName=ms3000002047025461, createdTime=Tue Feb 01 20:36:30 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-02-03 医生2394

    #CHMP#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1784849, encodeId=70a51e8484943, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Dec 22 05:50:27 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302708, encodeId=7cc91302e08fa, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372752, encodeId=d1fb13e275295, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189586, encodeId=67e8118958642, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbeb6410632, createdName=ms3000002047025461, createdTime=Tue Feb 01 20:36:30 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-02-03 yulin2006

    #Dupixent#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1784849, encodeId=70a51e8484943, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Dec 22 05:50:27 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302708, encodeId=7cc91302e08fa, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372752, encodeId=d1fb13e275295, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Feb 03 03:50:27 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189586, encodeId=67e8118958642, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbeb6410632, createdName=ms3000002047025461, createdTime=Tue Feb 01 20:36:30 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-02-01 ms3000002047025461

    学到了

    0

相关资讯

Lancet Respir Med：近期哮喘发作患者感染COVID-19后发生不良结局的风险加大

近期哮喘发作患者应该是COVID-19增强疫苗的优先群体。

JAMA Pediatrics：针对社会风险的干预措施与哮喘儿童住院率降低有关

基于这项研究，解决社会风险可能是改善儿童哮喘患者健康结局的重要措施。同时倡导在社区层面实施解决SDOH领域的政策。

Clin Transl Allergy：哮喘、特应性皮炎和变应性鼻炎与围产期精神障碍的关系

围产期是女性一个明显而重要的时期，受荷尔蒙和免疫分子变化的推动，导致精神障碍的易感性增加。受孕前有哮喘、特应性皮炎和过敏性鼻炎的病史与围产期精神障碍的风险增加有关。

Eur Respir J：呼吸道疾病人群的血嗜酸性粒细胞计数高于一般人群

嗜酸性粒细胞计数的分布和范围因研究人群而异，且受年龄、吸烟史、合并症等临床因素的影响，无论其严重程度如何，都应在治疗决策中加以考虑。

持续mepolizumab治疗能够让重度嗜酸性粒细胞性哮喘患者长期获益

持续mepolizumab治疗能够让重度嗜酸性粒细胞性哮喘患者获益，并支持血嗜酸性粒细胞作为mepolizumab治疗的生物标志物。

N Engl J Med：重度哮喘的生物治疗

生物制剂是未控制的重度嗜酸性粒细胞性哮喘的有效辅助治疗，能够显著降低2型高表型哮喘患者的急性加重率，并改善患者的生活质量和哮喘控制。

拓展阅读

ADC：儿童哮喘住院患者的出院标准

儿科哮喘出院标准缺乏共识和证据基础。常用标准包括支气管扩张剂频率、氧饱和度和呼吸评估。

中药汤剂、中成药、针灸疗法……共识推荐：中西医结合治疗儿童哮喘疗效确切

中西医结合才可能更有利于儿童哮喘的防治。

Antibiotics：早期抗生素暴露和儿童哮喘轨迹的关系

结果表明，早期接触抗生素与儿童早期持续性哮喘的风险增加有关。这加强了对早期抗生素使用的审查，特别是对不需要抗生素的常见病毒感染。

JAMA子刊：早期暴露于亚微米颗粒物PM1-10与儿童哮喘之间的关系

观察到儿童哮喘与较小颗粒物（如PM1）之间的相关性较高，结果表明，PM2.5与儿童哮喘的相关性主要是由PM1引起的。

circS100A11增强了儿童哮喘患者M2a巨噬细胞的激活和肺部炎症的发生

circRNAs的失调与多种人类疾病有关；然而，它在儿童哮喘中的作用尚未确定。

新研究发现，Masimo PVi®或有助于急诊科医生确定哮喘患儿发作的严重程度

研究人员表示，Masimo PVi作为“无创、快速、客观的工具”能帮助临床工作者预测呼吸阻塞病患儿的治疗应答和随访结果